Get the Stockscreener App
2.19
5.80%
0.12
Milestone Pharmaceuticals Inc Stock (MIST) Latest News
BlackRock, Inc. Reduces Stake in Milestone Pharmaceuticals Inc - GuruFocus.com
What was Milestone Pharmaceuticals Inc (MIST)’s performance in the last session? - US Post News
Insider’s View: Deciphering Fangdd Network Group Ltd (DUO)’s Financial Health Through Ratios - The Dwinnex
Loss-Making Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Expected To Breakeven In The Medium-Term - Yahoo Finance
What is HC Wainwright's Forecast for MIST FY2029 Earnings? - MarketBeat
HC Wainwright Analysts Decrease Earnings Estimates for MIST - MarketBeat
Vertex’s non-opioid pain drug gets FDA approval in milestone for company and research - BioPharma Dive
HC Wainwright Has Pessimistic Outlook of MIST Q1 Earnings - Defense World
Innocan Pharma's Subsidiary BI Sky Global Completes HRIPT Testing and Surpasses Important Sales Milestone - PR Newswire
Milestone Pharma Faces FDA Decision In MarchWill It Mean Heartbreak Or Happiness For Investors? - RTTNews
FY2029 Earnings Estimate for MIST Issued By HC Wainwright - Defense World
Milestone gears up for CARDAMYST launch in 2025 By Investing.com - Investing.com Australia
Milestone gears up for CARDAMYST launch in 2025 - Investing.com
Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC - The Manila Times
Game-Changing Heart Treatment Could Hit Market in 2025: Inside Milestone's Launch Strategy - StockTitan
Milestone Pharmaceuticals (NASDAQ:MIST) Receives “Buy” Rating from HC Wainwright - Defense World
H.C. Wainwright maintains $25 target on Milestone shares - MSN
HC Wainwright Reaffirms Buy Rating for Milestone Pharmaceuticals (NASDAQ:MIST) - MarketBeat
Shuttle Pharmaceuticals Hits Milestone in Patient Enrollment for Phase 2 Clinical Trial - Defense World
Medexus Secures FDA Approval for GRAFAPEX, Eyes $100M Revenue Milestone - TipRanks
Shuttle Pharma Reaches Milestone in Patient Enrollment for - GlobeNewswire
Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma - The Manila Times
Dogwood Therapeutics Poised For Data Milestone In Chemotherapy-Induced Neuropathic Pain In 2H 2025 - RTTNews
This Data Shows Just How Strong Milestone Pharmaceuticals Inc (NASDAQ: MIST) Stock Is - Stocks Register
NRx Pharmaceuticals Advances Towards FDA Approval with Key Stability Milestone for NRX-100 - MSN
Acadia Pharmaceuticals: Billion-Dollar Milestone and Global Expansion in 2025 - Yahoo Finance
Acadia Pharma Targets $1B Sales Milestone in 2025, Expands DAYBUE to European Market - StockTitan
C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology - The Manila Times
Xenon Pharmaceuticals Sets Sights on Key 2025 Milestones - TipRanks
Rakovina Therapeutics Announces Key Milestone in Cancer Drug Innovation in Collaboration with Variational AI - GlobeNewswire
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones - Yahoo Finance
MimiVax and UI Pharmaceuticals Achieve Milestone in SurVaxM Production for Glioblastoma Treatment - BioSpace
Goa to Lead in Pharma Growth as Zlata Pharma Sets Industry Milestones - Yahoo Finance
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Milestone Pharmaceuticals Awards 113,000 Stock Options to New Key Employees - StockTitan
Milestone Pharmaceuticals (NASDAQ:MIST) Shares Down 8.1%Time to Sell? - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) Trading Down 8.1% – Time to Sell? - Defense World
Milestone Pharmaceuticals Inc (NASDAQ: MIST): An Enticing Stock To Watch - Stocks Register
Hemogenyx Pharmaceuticals achieves new milestone with patient recruitment for first clinical trial - Proactive Investors USA
MIST Stock Hits 52-Week High at $2.42 Amid Positive Momentum - Investing.com Australia
Tonix Pharmaceuticals achieves key milestone with FDA review timeline for innovative Fibromyalgia treatment - Proactive Investors USA
Ionis gets a milestone approval; Another top FDA official to step down - BioPharma Dive
MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development - AccessWire
MIRA Pharmaceuticals Submits FDA Application for Breakthrough Pain Treatment Targeting $3.1B Market - StockTitan
Tonix Pharma’s TNX-102 SL Nears FDA Approval Milestone - TipRanks
Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of Cd228 X 4-1Bb Bispecific Molecule (Mabcalin Sgn-Bb228 (Prs-346) - Marketscreener.com
Novartis Ag ADR (NVS-N) QuotePress Release - The Globe and Mail
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement for PLUVICTO™ - Barchart
Jazz Pharmaceuticals Marks International Volunteers Day with Corporate Impact Milestone - StockTitan
Medigene Receives Milestone Payment from Regeneron Pharmaceuticals, Inc. - Marketscreener.com
Candel therapeutics chief medical officer sells $63,482 in stock - Investing.com
Medexus and medac Conclude Negotiations to Amend US Treosulfan Agreement, Setting Regulatory Milestone Amounts and Payment Schedule - Newsfile
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):